Conflict of Interest Disclosure

Disclosure of Conflict of Interest: Amy Abernethy
The conflict of interest policy of the National Academies of Sciences, Engineering, and Medicine (http://www.nationalacademies.org/coi) prohibits the appointment of an individual to a committee authoring a Consensus Study Report if the individual has a conflict of interest that is relevant to the task to be performed An exception to this prohibition is permitted if the National Academies determines that the conflict is unavoidable and the conflict is publicly disclosed A determination of a conflict of interest for an individual is not an assessment of that individual's actual behavior or character or ability to act objectively despite the conflicting interest.
Dr. Amy Abernethy has a conflict of interest in relation to her service on the Committee on Creating a Framework for Emerging Science, Technology, and Innovation in Health and Medicine because she is President of Product Development and Chief Medical Officer at Verily, a subsidiary of Alphabet, Inc. that focuses on the development of tools to use the increasing availability of health information and computing power to advance precision health. Dr. Abernethy also serves on the Board of EQRx, owns securities in 10x Genomics, Adaptive Bio, Beam Therapeutics, BeiGene, BridgeBio, Kura Oncology, and Organon, and holds an equity interest in Iterative Scopes.
The National Academies has concluded that in order for the committee to accomplish the tasks for which it was established, its membership must include at least one person who has current experience addressing the opportunities and challenges presented by innovation in health and medicine from the perspective of both the private sector and government oversight agencies. As described in her biographical summary, Dr. Abernethy has both extensive current experience focused on technology platforms enabling clinical research in the private sector and recent regulatory and government oversight experience as Principal Deputy Commissioner of the Food and Drug Administration.
The National Academies has determined that the experience and expertise of the individual is needed for the committee to accomplish the task for which it has been established. The National Academies could not find another available individual with the equivalent experience and expertise who does not have a conflict of interest. Therefore, the National Academies has concluded that the conflict is unavoidable.
The National Academies believes that Dr. Abernethy can serve effectively as a member of the committee, and the committee can produce an objective report, taking into account the composition of the committee, the work to be performed, and the procedures to be followed in completing the study.

Disclosure of Conflict of Interest: R. Alta Charo
The conflict of interest policy of the National Academies of Sciences, Engineering, and Medicine (http://www.nationalacademies.org/coi) prohibits the appointment of an individual to a committee authoring a Consensus Study Report if the individual has a conflict of interest that is relevant to the task to be performed An exception to this prohibition is permitted if the National Academies determines that the conflict is unavoidable and the conflict is publicly disclosed A determination of a conflict of interest for an individual is not an assessment of that individual's actual behavior or character or ability to act objectively despite the conflicting interest.
Prof. Alta Charo has a conflict of interest in relation to her service on the Committee on Creating a Framework for Emerging Science, Technology, and Innovation in Health and Medicine because she is a consultant to several for-profit companies involved in the development of innovative products and services in the area of health and medicine, including Johnson and Johnson (on ethical trial design), Colossal Biosciences, and Gameto. She also serves on the ethics advisory boards of eGenesis and Vertex Pharmaceuticals.
The National Academies has concluded that in order for the committee to accomplish the tasks for which it was established, its membership must include at least one person who has current wide-ranging expertise in ethical, regulatory, and governance issues associated with emerging technologies in health and medicine. As described in her biographical summary, Prof. Charo has current experience working with private sector, federal agency, and public-private stakeholders addressing ethical, regulatory, and governance issues arising from emerging technologies in health and medicine.
The National Academies has determined that the experience and expertise of the individual is needed for the committee to accomplish the task for which it has been established. The National Academies could not find another available individual with the equivalent experience and expertise who does not have a conflict of interest. Therefore, the National Academies has concluded that the conflict is unavoidable.
The National Academies believes that Prof. Charo can serve effectively as a member of the committee, and the committee can produce an objective report, taking into account the composition of the committee, the work to be performed, and the procedures to be followed in completing the study.

Disclosure of Conflict of Interest: Hana El-Samad
The conflict of interest policy of the National Academies of Sciences, Engineering, and Medicine (http://www.nationalacademies.org/coi) prohibits the appointment of an individual to a committee authoring a Consensus Study Report if the individual has a conflict of interest that is relevant to the task to be performed An exception to this prohibition is permitted if the National Academies determines that the conflict is unavoidable and the conflict is publicly disclosed A determination of a conflict of interest for an individual is not an assessment of that individual's actual behavior or character or ability to act objectively despite the conflicting interest.
Dr. El-Samad has a conflict of interest in relation to her service on the Committee on Creating a Framework for Emerging Science, Technology, and Innovation in Health and Medicine because she is a founding principal investigator of the biotechnology company Altos Labs and serves on the science advisory board of Sestina Bio.
The National Academies has concluded that in order for the committee to accomplish the tasks for which it was established, its membership must include at least one person who has current experience in the development and start-up commercialization of emerging technology in health and medicine. As described in her biographical summary, Dr. El-Samad plays a leadership role in overseeing regulatory, and governance issues associated with emerging health technologies as a founding principal investigator of Altos Labs.
The National Academies has determined that the experience and expertise of the individual is needed for the committee to accomplish the task for which it has been established. The National Academies could not find another available individual with the equivalent experience and expertise who does not have a conflict of interest. Therefore, the National Academies has concluded that the conflict is unavoidable.
The National Academies believes that Dr. El-Samad can serve effectively as a member of the committee, and the committee can produce an objective report, taking into account the composition of the committee, the work to be performed, and the procedures to be followed in completing the study.

Disclosure of Conflict of Interest: Jianying Hu
The conflict of interest policy of the National Academies of Sciences, Engineering, and Medicine (http://www.nationalacademies.org/coi) prohibits the appointment of an individual to a committee authoring a Consensus Study Report if the individual has a conflict of interest that is relevant to the task to be performed An exception to this prohibition is permitted if the National Academies determines that the conflict is unavoidable and the conflict is publicly disclosed A determination of a conflict of interest for an individual is not an assessment of that individual's actual behavior or character or ability to act objectively despite the conflicting interest.
Dr. Jianying Hu has a conflict of interest in relation to her service on the Committee on Creating a Framework for Emerging Science, Technology, and Innovation in Health and Medicine because she is an IBM Fellow, Director of Healthcare and Life Sciences (HCLS) Research, and Global Science Leader of AI for Healthcare at IBM Research.
The National Academies has concluded that in order for the committee to accomplish the tasks for which it was established, its membership must include at least one person with expertise and knowledge of current and potential future developments in the contribution that major information technology companies make to innovation in health and medicine in areas such as artificial intelligence and machine learning, and the associated opportunities and challenges from the perspective of those companies. As described in her biographical summary, Dr. Hu has extensive experience in machine learning, artificial intelligence, and data mining at leading private sector companies including Bell Laboratories and her current leadership roles at IBM Research.
The National Academies has determined that the experience and expertise of the individual is needed for the committee to accomplish the task for which it has been established. The National Academies could not find another available individual with the equivalent experience and expertise who does not have a conflict of interest. Therefore, the National Academies has concluded that the conflict is unavoidable.
The National Academies believes that Dr Hu can serve effectively as a member of the committee, and the committee can produce an objective report, taking into account the composition of the committee, the work to be performed, and the procedures to be followed in completing the study.